Spinning off Small Companies
This article was originally published in Start Up
Executive SummaryThe post-merger cutting room floor creates a great source of new companies and products--it’s good asset management for Big Pharma, and it’s good for medical entrepreneurs. But culturally and structurally, most large companies just can’t go along with the business logic of spin-offs. Technology that does get spun off is most often completely peripheral to the parent’s business--e.g., in vitro diagnostic applications or software and equipment systems from a drug company.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?